New HIV Treatment Works for Drug-Resistant Infections

For people living with HIV who've watched their treatment options narrow as the virus becomes resistant to common drugs, a new combination therapy is changing the game.

Researchers at UC San Francisco studied 46 patients using a long-acting treatment that pairs two drugs: lenacapavir and cabotegravir. Nearly three-quarters of participants had developed resistance to standard medications, and more than half still had detectable virus levels when they started.

The results stunned even the researchers. Every single participant who began treatment with detectable HIV brought the virus under control within 13 weeks. After nearly two years of follow-up, all patients maintained undetectable viral loads, the ultimate goal of HIV therapy.

Unlike daily pills that require strict adherence, these medications work for weeks or months after a single dose. That's life-changing for people who struggle with daily medication routines or face barriers to consistent care.

"Clinicians are already starting to use these two drugs together, and until now we've had very little evidence to guide us," said Dr. Monica Gandhi, the study's senior author and a UCSF professor of medicine. "This is the largest group studied on this combination, and we think these findings could help providers have more confidence using it."

The timing couldn't be better. The only currently approved long-acting HIV combination includes rilpivirine, a drug that many patients develop resistance to over time. Rilpivirine also isn't available in low and middle-income countries where HIV rates remain highest.

The Ripple Effect

This new approach attacks HIV differently than existing treatments, opening doors for patients who've run out of options. Both lenacapavir and cabotegravir are becoming more widely available globally, including through agreements allowing generic versions in lower-income countries.

The treatment isn't yet officially approved for this use, and two clinical trials are planned to study it further. But the compelling real-world results are already influencing how doctors care for their patients today.

For the estimated millions of people worldwide living with drug-resistant HIV, this research represents more than just data. It's proof that science keeps finding new ways forward, even when the path seems blocked.